Malaysia

Understand the key components of the Malaysia Medical Device Registration Dossier for Class B, C and D device submissions.

Enter Southeast Asia’s dental market with a clear strategy: navigate regulatory complexity, sequence market entry, and retain control of registrations to scale efficiently.

Learn about Cisema’s redesigned website with faster performance, clearer navigation and expanded Asia Pacific coverage.

Learn how Malaysia classifies drug–medical device combination products and how the PMOA determines pathways and compliance responsibilities.

Learn about Malaysia’s conformity assessment bodies — including CAB evaluation routes, risk classifications, and MDA registration steps.

Learn about license validity and renewal rules for medical devices in Southeast Asia.

Learn how to register cosmetics in Malaysia under NPRA’s notification system aligned with the ASEAN Cosmetic Directive.

Explore fast-track medical device registration in Southeast Asia, cut timelines by 6–12 months, and accelerate market entry with Cisema.

Explore the medical device market opportunities, regulations, and registration pathways across Malaysia, Singapore, Vietnam, and other key ASEAN countries.

MDA will issue only electronic establishment licenses, affecting medical device manufacturers, importers, and distributors.

New WHO CRP pathway enables faster MDA review of eligible WHO-prequalified IVDs.

New MDA guidance introduces a risk-based framework for managing post-registration medical device changes, including software updates and SaMD.

The full implementation of the reliance program creates new opportunities for manufacturers to accelerate regional market entry by strategically leveraging approvals across both jurisdictions.

Malaysia’s latest regulatory updates expand electronic labelling for pharmaceuticals and simplify medical device label requirements for foreign manufacturers.

Malaysia’s MDA has issued major updates affecting medical device classification, special access exemptions, and management of obsolete and discontinued devices under the Medical Device Act 2012

Malaysia’s MDA publishes the 7th edition of guidance on medical device labelling, with new e-labelling, e-IFU, and accessibility requirements

Circular No. 1/2026 clarifies regulatory requirements for medical device procurement tenders, such as licensing and GDPMD compliance.

Malaysia’s NPRA introduces reliance and priority review pathways for additional indications of registered innovator drugs.

Malaysia’s MDA withdraws personal use medical device importation Guidance Document, directing stakeholders to updated exemption requirements.

Malaysia’s NPRA mandates DEG and EG testing for high-risk oral liquid products, with mandatory compliance starting April 1, 2027.

Malaysia’s MDA and Thailand’s FDA launch a medical device reliance pilot to accelerate market access for Class B–D devices.

Malaysia clarifies that medical device tenders count as market placement, triggering licensing and compliance requirements.

Malaysia’s NPRA issues Directive No. 7 of 2026 mandating the Malaysian Guideline for GCP 5th Edition for clinical trials.

Malaysia’s MDA will regulate aesthetic and cosmetic medical devices under the Medical Device (Designated Medical Devices) Order 2026.

NPRA Circular No. 1/2026 updates Malaysia’s cosmetic ingredient annexes to align with the ASEAN Cosmetic Directive

Malaysia’s MDA introduces a two-year validity for Product Classification Letters from May 1, 2025 – see timelines and requirements.

Malaysia MDA's Draft 7th Edition labelling requirements introduce broader e-labelling requirements and stronger accessibility standards.

Malaysia’s MDA has increased Class A medical device registration fees effective January 2026 — impacting all new and renewal submissions.

From Sept 2025, Malaysia and Singapore launch a 6-month pilot to fast track medical device registration across ASEAN. Contact Cisema today.

Malaysia and China launch a regulatory reliance pilot to streamline IVD medical device registration and accelerate cross-border market access.